Mineralys Therapeutics Stock (NASDAQ:MLYS)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$39.90

52W Range

$8.24 - $44.80

50D Avg

$34.09

200D Avg

$18.45

Market Cap

$2.69B

Avg Vol (3M)

$1.64M

Beta

0.40

Div Yield

MLYS Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 10, 2023

Website

MLYS Performance

MLYS Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-192.40M	$-84.66M	$-31.48M
Net Income	$-177.81M	$-71.90M	$-29.80M
EBITDA	$-192.40M	$-84.66M	$-31.48M
Basic EPS	$-3.66	$-1.99	$-0.73
Diluted EPS	$-3.66	$-1.99	$-0.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 13, 25 | 4:30 PM

Q1 25May 12, 25 | 4:30 PM

Q4 24Feb 12, 25 | 8:30 AM

Peer Comparison

Ticker	Company
RXRX	Recursion Pharmaceuticals, Inc.
APLS	Apellis Pharmaceuticals, Inc.
BEAM	Beam Therapeutics Inc.
CDTX	Cidara Therapeutics, Inc.
NTLA	Intellia Therapeutics, Inc.
XENE	Xenon Pharmaceuticals Inc.
SRRK	Scholar Rock Holding Corporation
CNTA	Centessa Pharmaceuticals plc
IMVT	Immunovant, Inc.
APGE	Apogee Therapeutics, Inc.